Skip to search formSkip to main contentSkip to account menu

RWJ 270201

Known as: RWJ-270201, RWJ270201 
National Institutes of Health

Related topics

Related topics

2 relations
BCX 1812

Broader (1)

peramivir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
High-performance liquid chromatographic enantioseparation of unnatural β-amino acids on chiral stationary phases
The enantiomers of five monoterpene-based 2-amino carboxylic acids were directly separated on chiral stationary phases containing… 
2004
2004
Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs.
Highly Cited
2002
Highly Cited
2002
Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds.
Highly Cited
2002
Highly Cited
2002
Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
2002
2002
Oral Administration of Cyclopentane Neuraminidase Inhibitors Protects Ferrets against Influenza Virus Infection
ABSTRACT Several cyclopentane inhibitors of influenza virus neuraminidase that have inhibitory activities in tissue culture… 
Review
2001
Review
2001
RWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenza.
The influenza virus neuraminidase (NA) is important in the pathogenesis of infection and, thus, is an attractive target for… 
2001
2001
Pharmacodynamic Evaluation of RWJ-270201, a Novel Neuraminidase Inhibitor, in a Lethal Murine Model of Influenza Predicts Efficacy for Once-Daily Dosing
ABSTRACT We examined RWJ-270201 in a lethal model of influenza in BALB/c mice. The aim was to delineate the pharmacodynamically… 
2001
2001
Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201.
2001
2001
Primary immune system effects of the orally administered cyclopentane neuraminidase inhibitor RWJ-270201 in influenza virus-infected mice.
Review
2000
Review
2000
RWJ-270201 BioCryst Pharmaceuticals/Johnson & Johnson.
RWJ-270201, the lead compound in a series of influenza neuraminidase inhibitors, is under development by BioCryst for the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)